Please login to the form below
Vytorin
This page shows the latest Vytorin news and features for those working in and with pharma, biotech and healthcare.
CETP inhibitor class finally dies as Merck abandons anacetrapib
ezetimibe) and sister product Vytorin (ezetimibe plus simvastatin) - into a blockbuster franchise.
Latest news
-
Merck & Co's anacetrapib data fails to generate much excitement
selling Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) in this therapeutic area despite a small effect on cardiovascular outcomes.
-
FDA panel rejects cardiovascular outcomes claim for Vytorin
FDA panel rejects cardiovascular outcomes claim for Vytorin. Merck &Co fail to convince regulator's advisors. ... The trial started around 10 years ago - shortly after Vytorin was launched onto the market - with final results published last year.
-
Merck hopes for another Keytruda with new immunotherapy deal
But Merck has been hit by the on-going erosion to its cardiovascular and cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin).
-
Relief as study finds no cardiovascular risk with Januvia
Overall pharma sales fell 2% on the back of declines for cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) as well as immunotherapeutic Remicade (infliximab) which is facing biosimilar competition in
-
Merck's ezetimibe has 'modest' benefit when added to statins
under way nine years ago - shortly after Vytorin was first launched onto the market. ... Undeterred, Merck has said it will now file for approval of updated labelling for Vytorin and Zetia based on the results of IMPROVE-IT next year.
More from news
Approximately 4 fully matching, plus 34 partially matching documents found.
Latest from PMHub
-
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
The pharma giant’ s aim was to acquire the cholesterol inhibitor Vytorin, a product it had been hoping to develop before being been beaten to the finish line by its competitor.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Business Unit Head, Medical Communications, London
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
Subscribe to our email news alerts
- Brexit rebels win vote on European Medicines Agency alignment
- Moving annual total (MAT)
- MaxCyte gets green light for solid tumour cell therapy
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- AstraZeneca joins Merck in Brexit stockpiling effort
- NHS England to Vertex: come clean on Orkambi offer
- Random42 win Creativity International Award for Scientific Animation
- Merck & Co joins big pharma pricing pledge – but sceptics unconvinced
- Aurora partners with PIPHealth and taps into patient panels
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
PMHub
Six Degrees Medical Consulting
Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
